IVA Inventiva S.A.

FDA Catalyst Company
8.94
+0.09  (+1%)
Previous Close 8.85
Open 8.94
52 Week Low 8
52 Week High 16.93
Market Cap $365,409,546
Shares 40,873,551
Float 40,873,551
Enterprise Value $278,034,692
Volume 551
Av. Daily Volume 5,035
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/22/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 09/22/2021

Latest News

    • Cash position2 at €80.5m as of March 31, 2022
    • The Group did not generate any revenue in Q1 2022
    • Signature of a €50 million bullet credit facility agreement with the European Investment Bank
    • Update on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as for the two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine

    Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today reported…

    View Full Article
    • This credit facility is intended to support the progress and expansion of Inventiva's pipeline
    • The credit facility consists of two tranches of €25 million each
    • Credit agreement is part of the European Investment Bank's strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs  

    Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the signing of a €50 million…

    View Full Article
  1. Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the abstract "Lanifibranor, a pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH" has been selected for oral presentation during the third International Conference on Fatty Liver to be held from the 28th to the 30th of April 2022 in Vienna, Austria.


     

    This abstract focuses on the improvement of markers of cardiometabolic health in patients with NASH treated with lanifibranor…

    View Full Article
  2. Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report, with the French "Autorité des Marchés Financiers" (AMF) and its 2021 Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (SEC).

    These documents can be accessed on the "Investors" section of the…

    View Full Article
    • FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed
    • The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023


     

    Daix (France), Long Island City (New York, United States), March 8, 2022 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has completed its safety review of the IND application and has concluded that the proof-of-concept Phase II combination trial with its lead drug candidate lanifibranor…

    View Full Article
View All Inventiva S.A. News